DRUG DEVELOPMENT: Pathway for Approving Antibacterial and Antifungal Drugs for Patients with Limited Treatment Options is Infrequently Used.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      INFECTION; DRUGS; PUBLIC health; UNITED States. Food & Drug Administration; BUSINESS revenue
    • Abstract:
      The article presents the discussion on antibacterial and antifungal infections resistant for available drugs being a serious public health challenge. Topics include Food and Drug Administration (FDA) using a certain pathway known as the limited population pathway for antibacterial and antifungal drugs (LPAD); and giving the limited market for drugs, sales revenue being insufficient covering development costs surviving in the antibacterial and antifungal drug market.